Radio and PodcastRadio and PodcastLive Radio & Podcasts
Ep192: Kate Haviland on Following the Science to Precision Immunology artwork
Science & Medicine

Ep192: Kate Haviland on Following the Science to Precision Immunology

The Long Run with Luke Timmerman by The Long Run with Luke Timmerman

Jan 8, 202601:26:06Science & Medicine

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

Related Episodes

Continue listening to more episodes from The Long Run with Luke Timmerman.